Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41

mAbs

Volumn 1, Issue 5, 2009, Pages 458-469

  Montgomery, Donna L ^a   Wang, Ying Jie ^a   Hrin, Renee ^a   Luftig, Micah ^b,d   Su, Bin ^a   Miller, Michael D ^a   Wang, Fubao ^a   Haytko, Peter ^a   Huang, Lingyi ^a   Vitelli, Salvatore ^a   Condra, Jon ^a   Liu, Xiaomei ^a   Hampton, Richard ^a   Carfi, Andrea ^b   Pessi, Antonello ^b   Bianchi, Elisabetta ^b   Joyce, Joseph ^a   Lloyd, Chris ^c   Geleziunas, Romas ^a,e   Bramhill, David ^a,f   King, Vicki M ^a   Finnefrock, Adam C ^a   Strohl, William ^a,g   An, Zhiqiang ^a,h   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b IRBM   (Italy)

^c MEDIMMUNE   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e GILEAD SCIENCES   (United States)

^f Research Corporation Technologies Inc   (United States)

^g CENTOCOR INC   (United States)

^h Epitomics Inc   (United States)

Author keywords

Affinity maturation; gp41; HIV 1; Monoclonal antibody; Neutralization; scFv

Indexed keywords

GLYCOPROTEIN 41; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; BINDING AFFINITY; COMPLEMENTARITY DETERMINING REGION; HEAVY CHAIN; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHOBICITY; LIGHT CHAIN; VIRUS STRAIN;

EID: 77953668210     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature 2008; 455:613-619
2. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004; 5:233-236 (Pubitemid 38332116)
3. Schiavone M, Quinto I, Scala G. Perspectives for a protective HIV-1 vaccine. Adv Pharmacol 2008; 56:423-452
4. Root MJ, Steger HK. HIV-1 gp41 as a target for viral entry inhibition. Curr Pharm Des 2004; 10:1805-1825 (Pubitemid 38647463)
5. Zhu P, Liu J, Bess J Jr, Chertova E, Lifson JD, Grise H, et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 2006; 441:847-852 (Pubitemid 43910414)
6. Choudhry V, Zhang MY, Dimitrova D, Prabakaran P, Dimitrov AS, Fouts TR, et al. Antibody-based inhibitors of HIV infection. Expert Opin Biol Ther 2006; 6:523-531
7. Debnath AK. Progress in identifying peptides and small-molecule inhibitors targeted to gp41 of HIV-1. Expert Opin Investig Drugs 2006; 15:465-478
8. Eckert DM, Kim PS. Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 2001; 70:777-810.
9. Munoz-Barroso I, Durell S, Sakaguchi K, Appella E, Blumenthal R. Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J Cell Biol 1998; 140:315-323 (Pubitemid 28078395)
10. Dimitrov AS, Louis JM, Bewley CA, Clore GM, Blumenthal R. Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation. Biochemistry 2005; 44:12471-12479 (Pubitemid 41324338)
11. Louis JM, Nesheiwat I, Chang L, Clore GM, Bewley CA. Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. J Biol Chem 2003; 278:20278-20285 (Pubitemid 36799226)
12. Root MJ, Kay MS, Kim PS. Protein design of an HIV-1 entry inhibitor. Science 2001; 291:884-888 (Pubitemid 32120761)
13. Eckert DM, Kim PS. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc Natl Acad Sci USA 2001; 98:11187-11192
14. Miller MD, Geleziunas R, Bianchi E, Lennard S, Hrin R, Zhang H, et al. A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc Natl Acad Sci USA 2005; 102:14759-14764 (Pubitemid 41457129)
15. Luftig MA, Mattu M, Di Giovine P, Geleziunas R, Hrin R, Barbato G, et al. Structural basis for HIV-1 neutralization by a gp41 fusion intermediate- directed antibody. Nat Struct Mol Biol 2006; 13:740-747 (Pubitemid 44175168)
16. Nelson JD, Kinkead H, Brunel FM, Leaman D, Jensen R, Louis JM, et al. Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. Virology 2008; 377:170-183
17. Gustchina E, Louis JM, Lam SN, Bewley CA, Clore GM. A monoclonal Fab derived from a human nonimmune phage library reveals a new epitope on gp41 and neutralizes diverse human immunodeficiency virus type 1 strains. J Virol 2007; 81:12946-12953 (Pubitemid 350156932)
18. Choudhry V, Zhang MY, Sidorov IA, Louis JM, Harris I, Dimitrov AS, et al. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. Virology 2007; 363:79-90.
19. Bianchi E, Finotto M, Ingallinella P, Hrin R, Carella AV, Hou XS, et al. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection. Proc Natl Acad Sci USA 2005; 102:12903-12908 (Pubitemid 41279462)
20. Su B, Hrin R, Harvey BR, Wang YJ, Ernst RE, Hampton RA, et al. Automated high-throughput purification of antibody fragments to facilitate evaluation in functional and kinetic based assays. J Immunol Methods 2007; 322:94-103. (Pubitemid 46560585)
21. Moulard M, Phogat SK, Shu Y, Labrijn AF, Xiao X, Binley JM, et al. Broadly cross-reactive HIV-1- neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci USA 2002; 99:6913-6918 (Pubitemid 34526232)
22. Labrijn AF, Poignard P, Raja A, Zwick MB, Delgado K, Franti M, et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 2003; 77:10557-10565 (Pubitemid 37129699)
23. MacCallum RM, Martin AC, Thornton JM. Antibody-antigen interactions: contact analysis and binding site topography. J Mol Biol 1996; 262:732-745
24. Pini A, Bracci L. Phage display of antibody fragments. Curr Protein Pept Sci 2000; 1:155-169
25. Eckert DM, Shi Y, Kim S, Welch BD, Kang E, Poff ES, et al. Characterization of the steric defense of the HIV-1 gp41 N-trimer region. Protein Sci 2008; 17:2091-2100
26. Hrin R, Montgomery DL, Wang F, Condra J, An Z, Strohl WR, et al. In vitro synergy between peptides or neutralizing antibodies targeting the N- and C-terminal heptad repeats of HIV type 1 gp41. AIDS Res and Human Retroviruses 2008; 24:1537-1544
27. Hamburger AE, Kim S, Welch BD, Kay MS. Steric accessibility of the HIV-1 gp41 N-trimer region. J Biol Chem 2005; 280:12567-12572 (Pubitemid 40491074)
28. Lu M, Blacklow SC, Kim PS. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995; 2:1075-1082
29. Kliger Y, Shai Y. Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation. J Mol Biol 2000; 295:163-168 (Pubitemid 30045350)
30. McCafferty J, Fitzgerald KJ, Earnshaw J, Chiswell DJ, Link J, Smith R, et al. Selection and rapid purification of murine antibody fragments that bind a transition-state analog by phage display. Appl Biochem Biotechnol 1994; 47:157-171
31. Hawkins RE, Russell SJ, Winter G. Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J Mol Biol 1992; 226:889-896
32. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990; 348:552-554 (Pubitemid 120015109)
33. Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, et al. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 1996; 14:309-314 (Pubitemid 26149074)
34. Joyce JG, Hurni WM, Bogusky MJ, Garsky VM, Liang X, Citron MP, et al. Enhancement of alpha-helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design. J Biol Chem 2002; 277:45811-45820 (Pubitemid 35417559)
35. Myszka DG. Improving biosensor analysis. J Mol Recognit 1999; 12:279-284